Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Probenecid | The serum concentration of Cefamandole nafate can be increased when it is combined with Probenecid. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cefamandole nafate. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Cefamandole nafate. |
| Dicoumarol | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Dicoumarol. |
| Phenindione | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Phenindione. |
| Warfarin | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Coumarin. |
| (R)-warfarin | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Fluindione. |
| Clorindione | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when Cefamandole nafate is combined with (S)-Warfarin. |
| Lepirudin | The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole nafate. |
| Bivalirudin | The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefamandole nafate. |
| Alteplase | The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefamandole nafate. |
| Urokinase | The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefamandole nafate. |
| Reteplase | The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefamandole nafate. |
| Anistreplase | The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefamandole nafate. |
| Tenecteplase | The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefamandole nafate. |
| Abciximab | The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole nafate. |
| Drotrecogin alfa | The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefamandole nafate. |
| Streptokinase | The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefamandole nafate. |
| Argatroban | The therapeutic efficacy of Argatroban can be decreased when used in combination with Cefamandole nafate. |
| Ardeparin | The therapeutic efficacy of Ardeparin can be decreased when used in combination with Cefamandole nafate. |
| Fondaparinux | The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Cefamandole nafate. |
| Pentosan polysulfate | The therapeutic efficacy of Pentosan polysulfate can be decreased when used in combination with Cefamandole nafate. |
| Dipyridamole | The therapeutic efficacy of Dipyridamole can be decreased when used in combination with Cefamandole nafate. |
| Heparin | The therapeutic efficacy of Heparin can be decreased when used in combination with Cefamandole nafate. |
| Enoxaparin | The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Cefamandole nafate. |
| Epoprostenol | The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Cefamandole nafate. |
| Ximelagatran | The therapeutic efficacy of Ximelagatran can be decreased when used in combination with Cefamandole nafate. |
| Desmoteplase | The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Cefamandole nafate. |
| Defibrotide | The therapeutic efficacy of Defibrotide can be decreased when used in combination with Cefamandole nafate. |
| Ancrod | The therapeutic efficacy of Ancrod can be decreased when used in combination with Cefamandole nafate. |
| Beraprost | The therapeutic efficacy of Beraprost can be decreased when used in combination with Cefamandole nafate. |
| Prasugrel | The therapeutic efficacy of Prasugrel can be decreased when used in combination with Cefamandole nafate. |
| Rivaroxaban | The therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Cefamandole nafate. |
| Sulodexide | The therapeutic efficacy of Sulodexide can be decreased when used in combination with Cefamandole nafate. |
| Semuloparin | The therapeutic efficacy of Semuloparin can be decreased when used in combination with Cefamandole nafate. |
| Idraparinux | The therapeutic efficacy of Idraparinux can be decreased when used in combination with Cefamandole nafate. |
| Cangrelor | The therapeutic efficacy of Cangrelor can be decreased when used in combination with Cefamandole nafate. |
| Astaxanthin | The therapeutic efficacy of Astaxanthin can be decreased when used in combination with Cefamandole nafate. |
| Apixaban | The therapeutic efficacy of Apixaban can be decreased when used in combination with Cefamandole nafate. |
| Otamixaban | The therapeutic efficacy of Otamixaban can be decreased when used in combination with Cefamandole nafate. |
| Amediplase | The therapeutic efficacy of Amediplase can be decreased when used in combination with Cefamandole nafate. |
| Dabigatran etexilate | The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Cefamandole nafate. |
| Danaparoid | The therapeutic efficacy of Danaparoid can be decreased when used in combination with Cefamandole nafate. |
| Dalteparin | The therapeutic efficacy of Dalteparin can be decreased when used in combination with Cefamandole nafate. |
| Tinzaparin | The therapeutic efficacy of Tinzaparin can be decreased when used in combination with Cefamandole nafate. |
| Nadroparin | The therapeutic efficacy of Nadroparin can be decreased when used in combination with Cefamandole nafate. |
| Triflusal | The therapeutic efficacy of Triflusal can be decreased when used in combination with Cefamandole nafate. |
| Ticagrelor | The therapeutic efficacy of Ticagrelor can be decreased when used in combination with Cefamandole nafate. |
| Ditazole | The therapeutic efficacy of Ditazole can be decreased when used in combination with Cefamandole nafate. |
| Vorapaxar | The therapeutic efficacy of Vorapaxar can be decreased when used in combination with Cefamandole nafate. |
| Edoxaban | The therapeutic efficacy of Edoxaban can be decreased when used in combination with Cefamandole nafate. |
| Sodium citrate | The therapeutic efficacy of Sodium citrate can be decreased when used in combination with Cefamandole nafate. |
| Dextran | The therapeutic efficacy of Dextran can be decreased when used in combination with Cefamandole nafate. |
| Bemiparin | The therapeutic efficacy of Bemiparin can be decreased when used in combination with Cefamandole nafate. |
| Parnaparin | The therapeutic efficacy of Parnaparin can be decreased when used in combination with Cefamandole nafate. |
| Desirudin | The therapeutic efficacy of Desirudin can be decreased when used in combination with Cefamandole nafate. |
| Antithrombin Alfa | The therapeutic efficacy of Antithrombin Alfa can be decreased when used in combination with Cefamandole nafate. |
| Protein C | The therapeutic efficacy of Protein C can be decreased when used in combination with Cefamandole nafate. |
| Antithrombin III human | The therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Cefamandole nafate. |
| Letaxaban | The therapeutic efficacy of Letaxaban can be decreased when used in combination with Cefamandole nafate. |
| Darexaban | The therapeutic efficacy of Darexaban can be decreased when used in combination with Cefamandole nafate. |
| Betrixaban | The therapeutic efficacy of Betrixaban can be decreased when used in combination with Cefamandole nafate. |
| Nafamostat | The therapeutic efficacy of Nafamostat can be decreased when used in combination with Cefamandole nafate. |
| Monteplase | The therapeutic efficacy of Monteplase can be decreased when used in combination with Cefamandole nafate. |
| Gabexate | The therapeutic efficacy of Gabexate can be decreased when used in combination with Cefamandole nafate. |
| Protein S human | The therapeutic efficacy of Protein S human can be decreased when used in combination with Cefamandole nafate. |
| Brinase | The therapeutic efficacy of Brinase can be decreased when used in combination with Cefamandole nafate. |
| Melagatran | The therapeutic efficacy of Melagatran can be decreased when used in combination with Cefamandole nafate. |
| Saruplase | The therapeutic efficacy of Saruplase can be decreased when used in combination with Cefamandole nafate. |
| Tocopherylquinone | The therapeutic efficacy of Tocopherylquinone can be decreased when used in combination with Cefamandole nafate. |
| Dabigatran | The therapeutic efficacy of Dabigatran can be decreased when used in combination with Cefamandole nafate. |
| Troxerutin | The therapeutic efficacy of Troxerutin can be decreased when used in combination with Cefamandole nafate. |
| Edetic acid | The therapeutic efficacy of Edetic acid can be decreased when used in combination with Cefamandole nafate. |
| Reviparin | The therapeutic efficacy of Reviparin can be decreased when used in combination with Cefamandole nafate. |
| Dermatan sulfate | The therapeutic efficacy of Dermatan sulfate can be decreased when used in combination with Cefamandole nafate. |
| SR-123781A | The therapeutic efficacy of SR-123781A can be decreased when used in combination with Cefamandole nafate. |
| Disulfiram | The risk or severity of adverse effects can be increased when Cefamandole nafate is combined with Disulfiram. |
| Furosemide | Furosemide may decrease the excretion rate of Cefamandole nafate which could result in a higher serum level. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cefamandole nafate. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Cefamandole nafate. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Cefamandole nafate is combined with Cocaine. |